世界の樹状細胞癌ワクチン免疫療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5694 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、樹状細胞癌ワクチン免疫療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（プロベンジ、アプセデン、CreaVax、その他）、用途別市場規模（小児科、成人用）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・樹状細胞癌ワクチン免疫療法の市場動向 ・企業の競争状況、市場シェア ・樹状細胞癌ワクチン免疫療法の種類別市場規模と予測2016-2027（プロベンジ、アプセデン、CreaVax、その他） ・樹状細胞癌ワクチン免疫療法の用途別市場規模と予測2016-2027（小児科、成人用） ・樹状細胞癌ワクチン免疫療法の北米市場規模2016-2027（アメリカ、カナダ） ・樹状細胞癌ワクチン免疫療法の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・樹状細胞癌ワクチン免疫療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・樹状細胞癌ワクチン免疫療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・樹状細胞癌ワクチン免疫療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Lineage Cell Therapeutics、AVAX Technologies、DCPrime、Gradalis、Heat Biologics、ImmunoCellular Therapeutics、Immunicum、MolecuVax、Northwest Biotherapeutics、Pique Therapeutics、Regeneus、Tessa Therapeutics、Vaccinogen、XEME Biopharma） ・結論

Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.

Market Analysis and Insights: Global Dendritic Cell Cancer Vaccine Immunotherapy Market
The global Dendritic Cell Cancer Vaccine Immunotherapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Dendritic Cell Cancer Vaccine Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Dendritic Cell Cancer Vaccine Immunotherapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Dendritic Cell Cancer Vaccine Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Dendritic Cell Cancer Vaccine Immunotherapy market.

Global Dendritic Cell Cancer Vaccine Immunotherapy Scope and Market Size
Dendritic Cell Cancer Vaccine Immunotherapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Dendritic Cell Cancer Vaccine Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Provenge
Apceden
CreaVax
Others

Segment by Application
Pediatrics
Adults

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Lineage Cell Therapeutics
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
ImmunoCellular Therapeutics
Immunicum
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Provenge
1.2.3 Apceden
1.2.4 CreaVax
1.2.5 Others
1.3 Market by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Perspective (2016-2027)
2.2 Dendritic Cell Cancer Vaccine Immunotherapy Growth Trends by Regions
2.2.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Share by Regions (2016-2021)
2.2.3 Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Regions (2022-2027)
2.3 Dendritic Cell Cancer Vaccine Immunotherapy Industry Dynamic
2.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Trends
2.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
2.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
2.3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue
3.1.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue (2016-2021)
3.1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Players (2016-2021)
3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Dendritic Cell Cancer Vaccine Immunotherapy Revenue
3.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio
3.4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2020
3.5 Dendritic Cell Cancer Vaccine Immunotherapy Key Players Head office and Area Served
3.6 Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
3.7 Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Dendritic Cell Cancer Vaccine Immunotherapy Breakdown Data by Type
4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2016-2021)
4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2022-2027)

5 Dendritic Cell Cancer Vaccine Immunotherapy Breakdown Data by Application
5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2016-2021)
5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2016-2027)
6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type
6.2.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021)
6.2.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027)
6.2.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2027)
6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application
6.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021)
6.3.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027)
6.3.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2027)
6.4 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
6.4.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021)
6.4.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2016-2027)
7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type
7.2.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021)
7.2.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027)
7.2.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2027)
7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application
7.3.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021)
7.3.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027)
7.3.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2027)
7.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
7.4.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021)
7.4.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2016-2027)
8.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type
8.2.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application
8.3.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region
8.4.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2016-2027)
9.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type
9.2.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021)
9.2.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027)
9.2.3 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2027)
9.3 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application
9.3.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021)
9.3.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027)
9.3.3 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2027)
9.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
9.4.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021)
9.4.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2016-2027)
10.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type
10.2.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application
10.3.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country
10.4.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Lineage Cell Therapeutics
11.1.1 Lineage Cell Therapeutics Company Details
11.1.2 Lineage Cell Therapeutics Business Overview
11.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.1.4 Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.1.5 Lineage Cell Therapeutics Recent Development
11.2 AVAX Technologies
11.2.1 AVAX Technologies Company Details
11.2.2 AVAX Technologies Business Overview
11.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.2.4 AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.2.5 AVAX Technologies Recent Development
11.3 DCPrime
11.3.1 DCPrime Company Details
11.3.2 DCPrime Business Overview
11.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.3.4 DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.3.5 DCPrime Recent Development
11.4 Gradalis
11.4.1 Gradalis Company Details
11.4.2 Gradalis Business Overview
11.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.4.4 Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.4.5 Gradalis Recent Development
11.5 Heat Biologics
11.5.1 Heat Biologics Company Details
11.5.2 Heat Biologics Business Overview
11.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.5.4 Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.5.5 Heat Biologics Recent Development
11.6 ImmunoCellular Therapeutics
11.6.1 ImmunoCellular Therapeutics Company Details
11.6.2 ImmunoCellular Therapeutics Business Overview
11.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.6.4 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.6.5 ImmunoCellular Therapeutics Recent Development
11.7 Immunicum
11.7.1 Immunicum Company Details
11.7.2 Immunicum Business Overview
11.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.7.4 Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.7.5 Immunicum Recent Development
11.8 MolecuVax
11.8.1 MolecuVax Company Details
11.8.2 MolecuVax Business Overview
11.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.8.4 MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.8.5 MolecuVax Recent Development
11.9 Northwest Biotherapeutics
11.9.1 Northwest Biotherapeutics Company Details
11.9.2 Northwest Biotherapeutics Business Overview
11.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.9.4 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.9.5 Northwest Biotherapeutics Recent Development
11.10 Pique Therapeutics
11.10.1 Pique Therapeutics Company Details
11.10.2 Pique Therapeutics Business Overview
11.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.10.4 Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.10.5 Pique Therapeutics Recent Development
11.11 Regeneus
11.11.1 Regeneus Company Details
11.11.2 Regeneus Business Overview
11.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.11.4 Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.11.5 Regeneus Recent Development
11.12 Tessa Therapeutics
11.12.1 Tessa Therapeutics Company Details
11.12.2 Tessa Therapeutics Business Overview
11.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.12.4 Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.12.5 Tessa Therapeutics Recent Development
11.13 Vaccinogen
11.13.1 Vaccinogen Company Details
11.13.2 Vaccinogen Business Overview
11.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.13.4 Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.13.5 Vaccinogen Recent Development
11.14 XEME Biopharma
11.14.1 XEME Biopharma Company Details
11.14.2 XEME Biopharma Business Overview
11.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Introduction
11.14.4 XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
11.14.5 XEME Biopharma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Provenge
Table 3. Key Players of Apceden
Table 4. Key Players of CreaVax
Table 5. Key Players of Others
Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Regions (2016-2021)
Table 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Regions (2022-2027)
Table 12. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends
Table 13. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
Table 14. Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
Table 15. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
Table 16. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players (2016-2021)
Table 18. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2020)
Table 19. Ranking of Global Top Dendritic Cell Cancer Vaccine Immunotherapy Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
Table 23. Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2016-2021)
Table 27. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2016-2021)
Table 31. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2022-2027) & (US$ Million)
Table 63. Lineage Cell Therapeutics Company Details
Table 64. Lineage Cell Therapeutics Business Overview
Table 65. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 66. Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 67. Lineage Cell Therapeutics Recent Development
Table 68. AVAX Technologies Company Details
Table 69. AVAX Technologies Business Overview
Table 70. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 71. AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 72. AVAX Technologies Recent Development
Table 73. DCPrime Company Details
Table 74. DCPrime Business Overview
Table 75. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 76. DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 77. DCPrime Recent Development
Table 78. Gradalis Company Details
Table 79. Gradalis Business Overview
Table 80. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 81. Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 82. Gradalis Recent Development
Table 83. Heat Biologics Company Details
Table 84. Heat Biologics Business Overview
Table 85. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 86. Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 87. Heat Biologics Recent Development
Table 88. ImmunoCellular Therapeutics Company Details
Table 89. ImmunoCellular Therapeutics Business Overview
Table 90. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 91. ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 92. ImmunoCellular Therapeutics Recent Development
Table 93. Immunicum Company Details
Table 94. Immunicum Business Overview
Table 95. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 96. Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 97. Immunicum Recent Development
Table 98. MolecuVax Company Details
Table 99. MolecuVax Business Overview
Table 100. MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 101. MolecuVax Recent Development
Table 102. Northwest Biotherapeutics Company Details
Table 103. Northwest Biotherapeutics Business Overview
Table 104. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 105. Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 106. Northwest Biotherapeutics Recent Development
Table 107. Pique Therapeutics Company Details
Table 108. Pique Therapeutics Business Overview
Table 109. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 110. Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 111. Pique Therapeutics Recent Development
Table 112. Regeneus Company Details
Table 113. Regeneus Business Overview
Table 114. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 115. Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 116. Regeneus Recent Development
Table 117. Tessa Therapeutics Company Details
Table 118. Tessa Therapeutics Business Overview
Table 119. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 120. Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 121. Tessa Therapeutics Recent Development
Table 122. Vaccinogen Company Details
Table 123. Vaccinogen Business Overview
Table 124. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 125. Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 126. Vaccinogen Recent Development
Table 127. XEME Biopharma Company Details
Table 128. XEME Biopharma Business Overview
Table 129. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product
Table 130. XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021) & (US$ Million)
Table 131. XEME Biopharma Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type: 2020 VS 2027
Figure 2. Provenge Features
Figure 3. Apceden Features
Figure 4. CreaVax Features
Figure 5. Others Features
Figure 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application: 2020 VS 2027
Figure 7. Pediatrics Case Studies
Figure 8. Adults Case Studies
Figure 9. Dendritic Cell Cancer Vaccine Immunotherapy Report Years Considered
Figure 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Regions: 2020 VS 2027
Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Regions (2022-2027)
Figure 14. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players in 2020
Figure 15. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2020
Figure 17. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2016-2021)
Figure 18. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2022-2027)
Figure 19. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2016-2027)
Figure 21. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2016-2027)
Figure 22. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2016-2027)
Figure 23. United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2016-2027)
Figure 27. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2016-2027)
Figure 28. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2016-2027)
Figure 29. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2016-2027)
Figure 39. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2016-2027)
Figure 47. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2016-2027)
Figure 48. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2016-2027)
Figure 49. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2016-2027)
Figure 55. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Lineage Cell Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 59. AVAX Technologies Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 60. DCPrime Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 61. Gradalis Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 62. Heat Biologics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 63. ImmunoCellular Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 64. Immunicum Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 65. MolecuVax Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 66. Northwest Biotherapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 67. Pique Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 68. Regeneus Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 69. Tessa Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 70. Vaccinogen Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 71. XEME Biopharma Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

---